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Background: Growing evidence support an association between venous thromboembolism 
(VTE) and arterial thrombotic diseases (i.e. myocardial infarction (MI) and ischemic stroke). 
We aimed to study the association between VTE and future arterial events, and to determine 
the population attributable risk (PAR%) of arterial events by VTE in a large prospective 
cohort recruited from the general population. 
Methods and Results: In 1994-1995 and 1993-1997, 81 687 subjects were included in the 
Tromsø Study and in the Diet, Cancer and Health Study and followed to the date of incident 
venous and arterial events (MI or ischemic stroke), death or migration, or to the end of the 
study period (2010 and 2008, respectively). There were 1 208 cases of VTE and 90 
subsequent arterial events during a median follow-up of 12.2 years. An association between 
VTE and future arterial events was found in all women and men <65 years, but not in men 
>65 years. Women <65 years with VTE had 3.3-fold higher risk of arterial disease (adjusted 
HR 3.28, 95%CI 1.69-6.35) compared to women of the same age without VTE. The 
corresponding HR in men <65 years was 2.06 (95%CI: 1.32-3.20). Only 0.9% of the arterial 
events were attributed to VTE, and the VTE explained 63.8% of the risk of arterial events 
among VTE patients. 
Conclusions: Our findings imply that women and young men with VTE have higher risk of 
arterial thrombotic disease than those without VTE. However, only 1% of the arterial 
thrombotic events in the population are attributed to VTE. 
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Arterial thrombotic diseases (i.e. myocardial infarction (MI) and ischemic stroke) and venous 
thromboembolism (i.e. deep vein thrombosis (DVT) and pulmonary embolism (PE)) have 
traditionally been considered as separate diseases with distinct etiology and treatment 
strategies. However, later studies have suggested a potential link between arterial and venous 
thrombosis. A higher frequency of carotid plaques has been found in patients with 
unprovoked VTE compared to patients with provoked VTE and hospitalized controls.1 
Moreover, a study of consecutive autopsies reported an association between atherothrombosis 
and VTE,2 and the highest prevalence of previous hospitalization for MI and stroke was found 
among VTE patients in a case-control study of more than 60 000 VTE patients and population 
controls.3 
Growing evidence support an association between VTE and future arterial thrombotic 
events. In studies of patients with VTE, subjects with unprovoked events had higher risk of 
arterial thrombotic disease than patients with provoked events.4-7 However, the risk was 
assessed in selected cohorts (e.g. patients with a previous history of PE),4-6 or included a low 
number of study participants.7 A large population-based registry study, with more than 
200 000 subjects, reported that patients with VTE had substantially higher long-term 
incidence of subsequent arterial thrombotic diseases.8 However, information about potential 
confounders, such as body mass index (BMI), was not available in this study.8 In addition, the 
attributable risk and the population attributable risk of arterial thrombotic disease due to VTE 
were not reported. Such data are essential, as a considerable proportion of arterial events 
attributable to VTE could imply a role for long-term treatment to prevent subsequent arterial 
events in VTE patients.  
The aim of this study was to investigate the association between incident VTE and 
future risk of arterial thromboembolic events in a general population, and adjust for potential 




confounders such as BMI. We conducted individual-level analyses of two prospective 
population-based cohorts and assessed the absolute and relative risks of first-time arterial 




Subjects were recruited from the fourth survey of the Tromsø Study (conducted in 1994-95), 
and from the Diet, Cancer and Health (DCH) Study (conducted in 1993-97). The Tromsø 
Study and the DCH Study are population-based studies, with repeated health surveys of 
inhabitants in Tromsø, Norway, and Copenhagen and Aarhus, Denmark, respectively. The 
study populations have been described in detail elsewhere.9, 10 In the fourth survey of the 
Tromsø Study, all inhabitants aged 25 years or older were invited and 27 158 (77% of the 
eligible population) participated. In the DCH Study, all inhabitants living in the urban areas of 
Copenhagen and Aarhus were invited to participate if they were born in Denmark, between 50 
to 65 years of age and did not have a diagnosis of cancer in the Danish Cancer Registry at 
enrollment, and 57 054 subjects participated. 
The study was approved by the regional committees for research ethics in Tromsø, 
Aarhus and Copenhagen, respectively, and all subjects gave their informed written consent. 
Subjects who did not consent to medical research (n= 243) and subjects not officially 
registered as inhabitants of the municipalities at baseline (n= 44) were excluded from the 
study. Furthermore, subjects were excluded if they had a pre-baseline history of VTE (n= 
495), ischemic stroke (n= 163) or MI (n= 1 573). Thus, a total of 81 693 subjects were 
included, and followed from the dates of enrollment in Denmark (1993-97) and Norway 




(1994-95) through the end of the study periods in 2008 and 2010, respectively. The overall 
median follow-up time was 12.2 years. 
 
Atherosclerotic risk factors 
Baseline information was collected by physical examinations and self-administered 
questionnaires. Height and weight were measured, BMI calculated and blood pressure was 
recorded, as described elsewhere.11, 12 Detailed information on diabetes mellitus, 
hypertension, hypercholesterolemia, smoking, physical activity, education level and 
medication use including hormone replacement therapy, oral contraceptives, 
antihypertensives and lipid lowering drugs, was collected from self-administered 
questionnaires. Non-fasting blood samples were collected and total cholesterol measured as 
previously described.11, 12 Obesity was classified based on BMI according to the World Health 
Organization (WHO) definition.13 Hypertension was classified as mean systolic blood 
pressure ≥ 140 mmHg, mean diastolic blood pressure ≥ 90 mmHg, self-reported use of blood 
pressure lowering drugs, or self-reported hypertension. Hypercholesterolemia was classified 
as total serum cholesterol ≥ 6.5 mmol/l, self-reported use of lipid lowering drugs, or self-
reported hypercholesterolemia. 
 
Registry of VTE  
Only objectively verified symptomatic VTE events were included in the study and the VTE 
events were similarly validated and recorded in the Tromsø and the DCH Study. All first-time 
events of VTE during follow-up in the Tromsø Study were identified by searching the 
hospital discharge diagnosis registry, the autopsy registry, and the radiology procedure 




registry of the University Hospital of North Norway from date of enrollment (1994-95) to 
December 31, 2010, as previously described.14 A VTE event derived from the hospital 
discharge diagnosis registry or the radiology procedure registry, was verified and recorded 
when presence of clinical signs and symptoms of DVT or PE were combined with objective 
confirmatory tests (compression ultrasonography, venography, spiral computed tomography, 
perfusion-ventilation scan, pulmonary angiography, or autopsy), and resulted in a VTE 
diagnosis that required treatment. VTE cases from the autopsy registry were recorded when 
the death certificate indicated VTE as cause of death or as a significant condition contributing 
to death.  
In the DCH Study, all incident VTE events were identified by linking the cohort with 
the Danish National Patient Registry and the Danish National Death Registry by use of the 
civil registration number of the study participants from date of enrollment (1993-97) to April 
30, 2008, as described elsewhere.12 A VTE diagnosis was verified when typical clinical 
symptoms of VTE were combined with confirmatory diagnostic test results (ultrasound, 
venography, echocardiography, ventilation-perfusion lung scan, or computed tomography 
scan), or when autopsy verified VTE.  
In both studies, trained personnel reviewed the medical records for each potential 
VTE-case. Concurrent DVT and PE were registered as PE. Verified events were  classified as 
unprovoked or provoked based on the presence of provoking factors at the time of diagnosis, 
as previously described in detail.12, 14 In the last update of VTE events in the DCH Study (July 
2006 to April 2008), verified VTEs were not further classified. Therefore, 136 VTE patients 
had missing information on localization (DVT/PE) and 146 had missing on classification 
(unprovoked/provoked). 
  




Registry of arterial thrombotic events 
In the Tromsø Study, all first-time events of myocardial infarction and ischemic stroke were 
identified by searching the hospital and out-of hospital medical records, the autopsy registry 
and the death certificates, as previously described.11, 15 The national unique 11-digit 
identification number allowed linkage to national and local diagnosis registries and to the 
National Causes of Death Registry at Statistics Norway. Medical records were case validated 
by an independent endpoint committee. Slightly modified WHO MONICA/MORGAM 
criteria for myocardial infarction were used and these included clinical symptoms and signs, 
findings in electrocardiograms, values of cardiac biomarkers, and autopsy reports when 
applicable. Ischemic stroke was defined according to the WHO definition when CT or MRI 
scans had ruled out brain hemorrhage. In the DCH Study, potential cases of incident 
myocardial infarction and ischemic stroke were identified by linkage to the Danish National 
Patient Registry and the Danish Causes of Death Registry, as described elsewhere.16, 17 From 
baseline through 2003, potential MI cases were validated by direct review of medical records 
in accordance with the guidelines of the American Heart Association and the European 
Society of Cardiology for use in epidemiology. From January 2004 until end of follow up in 
April 2008, and for participants whose medical records were not available for review in the 
period 1993-2003, all participants with a diagnosis of MI were accepted as cases without 
further validation. These diagnoses had a positive predictive value above 90% in the Danish 
National Patient Registry. For ischemic stroke, the WHO definition18 was used and all cases 
were verified by CT, MRI, spinal fluid examination or autopsy.  
 
Statistical analyses 




Subjects who developed VTE during the study period contributed with non-exposed person-
time from the baseline inclusion date to the date of a diagnosis of VTE, and then with exposed 
person-time from the date of VTE and onwards. For each participant, non-exposed and 
exposed person-years were counted from the date of enrollment to the date of an incident 
diagnosis of arterial thrombotic disease (i.e. MI and ischemic stroke), the date the participant 
died or moved from the municipalities, or until the end of the study period (December 31, 
2010 Tromsø, and April 30, 2008 DCH), whichever came first. Subjects who died or moved 
from the municipalities during follow-up were censored at the date of migration or death. 
Subjects with VTE and an arterial event on the same day (n=6) were excluded from all 
analyses, since the temporal sequence of exposure and outcome could not be determined. 
Statistical analyses were performed with STATA version 12.0 (Stata Corporation, 
College Station, TX). Baseline differences between groups were tested by one-way ANOVA 
for continuous variables, and by chi-square for categorical variables. Crude incidence rates 
(IR) of arterial thrombotic disease were calculated and expressed as number of events per 
1000 person-years at risk. Cox proportional hazard regression models were used to estimate 
crude and multivariable adjusted hazard ratios (HR) with 95% confidence intervals (CI) for 
arterial thrombotic disease, MI and ischemic stroke. Age was used as time-scale, with 
participants’ age at study enrollment defined as entry-time, and exit-time defined as age at the 
censoring event (arterial thrombotic disease, death, migration or study end). The exposure 
variable (VTE) was included as a time-dependent covariate, i.e. no participants were 
registered with VTE at baseline, but the variable was updated for those who developed VTE 
during follow-up. The multivariable HRs were adjusted for age, BMI, diabetes, hypertension, 
hypercholesterolemia, smoking, physical activity, and education level. In addition, subgroup 
analyses of PE and DVT as exposure variables for arterial thrombotic disease were performed 
using the same time-varying approach. Statistical interactions between VTE and age or sex 




were tested by including cross-product terms in the proportional hazard model. Further 
analyses were stratified by sex and age (≥65 years). The proportional hazard assumption was 
verified by evaluating the parallelism between the curves of the log-log survivor function. 
In order to show the change in risk of arterial events over time, crude incidence rates 
of arterial thrombotic disease, MI and ischemic stroke were plotted against time (1, 3, 5, 7 and 
10 years) after an episode of VTE, DVT or PE, respectively, using GraphPad Prism version 
5.0 (GraphPad Software, San Diego, CA).  
Attributable risk (AR%), the proportion of events among the exposed subjects that can 
be explained by the exposure, was calculated from incidence rates of arterial thrombotic 
disease in the VTE (Ie) and non-VTE (I0) population (100% * (Ie – I0) / Ie). Population 
attributable risk fraction (PAR%), the proportion of events in the study population attributable 
to the exposure, was calculated using the incidence rates of arterial thrombotic disease in the 
general population (Ip) and in the non-VTE (I0) population (100% * (Ip – I0) / Ip ). 
 
Results 
In our population, 1 208 subjects with a first-time VTE event were identified, of which 90 
developed a subsequent incident arterial thrombotic event (i.e. MI and ischemic stroke). 
Baseline characteristics of study participants are shown in Table 1. Compared to those who 
developed arterial events only, those who developed an incident arterial thrombotic disease 
after a VTE event had higher mean age and BMI values, comprised higher proportions of 
subjects with diabetes, hypertension and hypercholesterolemia, and had a lower proportion of 
men and subjects who regularly performed exercise.  




Characteristics of the VTE events are shown in Table 2. Among the 1 208 VTE 
events, 648 (53.6%) were DVT and 424 (35.1%) were PE events. Moreover, 513 (42.5%) 
events were classified as provoked and 548 (45.4%) as unprovoked. The use of estrogens was 
associated with 208 (17.2% of the total and 35.1% of the female) VTE events, and 146 
(12.1%) of the VTE subjects had other medical conditions present at the time of VTE (Table 
2).  
Incidence rates and hazard ratios for arterial thrombotic diseases by VTE and subtypes 
of VTE are shown in Table 3. In total, there were 6 344 incident arterial thrombotic events 
(3 666 MIs and 2 678 ischemic strokes) during a median of 12.2 years of follow-up. In 
subjects without VTE, 6 254 arterial events were identified during a total of 967 604 person-
years of follow-up (IR 6.5 per 1000 person-years), while there were 90 arterial events during 
5 039 person-years of follow-up in subjects exposed to VTE (IR 17.9 per 1000 person-years). 
Overall, VTE was associated with a 35% (adjusted HR 1.35; 95% CI 1.09-1.66) increased risk 
of arterial thrombotic disease. Investigating the risk of MI and ischemic stroke separately 
yielded HRs of 1.31 (95% CI 1.00-1.72) and 1.33 (95% CI 0.96-1.84), respectively (Table 3). 
The attributable risk of arterial thrombotic disease among VTE patients was 63.8%, and 0.9% 
of the arterial events in the population were attributable to VTE. In subgroup analyses, PE, 
but not DVT, was associated with increased risk of arterial thrombotic disease (adjusted HR 
1.82; 95% CI 1.35-2.47), MI (adjusted HR 2.02; 95% CI 1.38-2.95), and ischemic stroke 
(adjusted HR 1.53; 95% CI 0.92-2.55) (Table 3). The incidence rate of arterial events in VTE 
subjects differed according to VTE type, and changed with time after the VTE episode 
(Figure 1). The highest crude incidence rate of arterial thrombotic disease (Figure 1a), MI 
(Figure 1b) and ischemic stroke (Figure 1c) was found the first year after a PE event.  
A significant statistical interaction was found between VTE and sex, and between 
VTE and age. When analyses were stratified by sex and the age of 65 years, the association 




between VTE and subsequent arterial thrombotic disease applied to all women and to men 
below 65 years of age (Table 4). Women below 65 years of age with VTE had a 3.3-fold 
higher risk of arterial thrombotic disease (adjusted HR 3.28; 95% CI 1.69-6.35), 3.6-fold 
higher risk of MI (adjusted HR 3.62; 95% CI 1.49-8.80) and 3.2-fold higher risk of ischemic 
stroke (adjusted HR 3.16; 95% CI 1.18-8.47) compared with women in the same age-group 
without VTE. Women aged 65 years or older had the highest incidence rates of arterial 
thrombotic disease (IR 24.1 per 1000 person-years) after a VTE event, and the absolute risk 
increase was also highest (14 additional events per 1000 persons per year). The relative risk 
estimates for arterial thrombotic diseases were 40-60% higher in women of this age group 
with VTE compared with no VTE (adjusted HR for arterial disease: 1.55; 95% CI 1.11-2.18, 
MI: 1.41; 0.89-2.24 and stroke: 1.66; 1.01-2.74). Men below 65 years of age with a VTE had 
2.1-fold higher relative risk of arterial thrombotic disease (adjusted HR 2.06; 95% CI 1.32-
3.20), 2.1-fold higher risk of MI (adjusted HR 2.11; 95% CI 1.22-3.65) and 2.0-fold higher 
risk of ischemic stroke (adjusted HR 1.95; 95% CI 0.93-4.12) compared with those without 
VTE, whereas no association was found between VTE and arterial events in men aged 65 
years or older (Table 4). Adjusting for the use of estrogens in women did not change the risk 
estimates (data not shown). In subgroup analyses, pulmonary embolism was associated with 
increased risk of arterial thrombotic disease in all women and men below 65 years (Table 4). 
A higher risk of myocardial infarction was found in both men and women below 65 years 
with PE compared with those without VTE (adjusted HRs 4.80; 95% CI 2.39-9.62 and 4.06; 
95% CI 1.00-16.40, respectively). Women below 65 years with DVT had higher risk of 
arterial thrombotic disease (adjusted HR 3.32; 95% CI 1.48-7.44), MI (adjusted HR 3.35; 
95% CI 1.07-10.46), and ischemic stroke (adjusted HR 3.66; 95% CI 1.17-11.42) compared 
with women in the same age-group without VTE, whereas no association was found in men 
below 65 with DVT. Moreover, no association was found between PE or DVT and arterial 




events in men aged 65 years or older. The lowest proportion of DVT and PE events were 
found in women below 65 years of age (Table 4). 
 





In the present study, incident venous thromboembolism was associated with increased risk of 
future myocardial infarction and ischemic stroke. Specifically, women of all ages and men 
below 65 years of age suffering from a VTE event had higher risk of major arterial thrombotic 
diseases compared with those without VTE. In women, PE and DVT provided similar risk 
estimates of arterial events, whereas PE rather than DVT appeared to predict arterial 
thrombotic diseases in men. The incidence rate of arterial events was highest the first year 
after a PE episode. The population attributable risk of arterial thrombotic disease by incident 
VTE was only 0.9%, and the VTE event explained 64% of the risk for arterial events in VTE 
patients. 
The mechanism behind the observed association between VTE and arterial thrombotic 
diseases is not fully understood. Potentially, atherosclerosis may initiate both venous and 
arterial thrombosis by a similar pro-thrombotic trigger, such as inflammation.19, 20 Prospective 
studies of general populations have, however, failed to confirm an association between 
atherosclerosis and VTE.21, 22 Moreover, growing evidence support the concept that traditional 
atherosclerotic risk factors including diabetes, hypertension and dyslipidemia are not 
associated with venous thrombosis.11, 23-26 Obesity and advancing age are shared risk factors 
for arterial and venous thrombosis. However, adjustments for age and BMI in addition to 
traditional atherosclerotic risk factors only modestly affected the risk estimates, indicating 
that these two common factors could not fully explain the observed association between VTE 
and risk of future MI. Modifiable risk factors such as smoking, diabetes, hypertension and 
hypercholesterolemia may change over time, and residual confounding by these factors 
cannot be ruled out. Moreover, unknown confounders may still be present, and could 
potentially explain the association. In a recently published study, common etiologic factors 
including genetic thrombophilia and procoagulant markers explained the increased risk of 




arterial cardiovascular disease after VTE.27 A family history of MI has been shown to be 
associated with both arterial thrombotic disease28, 29 and VTE,30, 31 suggesting a common 
genetic component for both diseases. Concordantly, some inherited thrombophilias have also 
been associated with arterial thrombosis.32, 33 Furthermore, several risk factors for VTE, 
including high levels of coagulation factors VIII, IX and XI, plasminogen activator inhibitor-1 
and von Willebrand factor, have been reported as risk factors for arterial cardiovascular 
disease.34, 35 
It is also possible that the observed association is not explained by common risk 
factors, but restricted to the events themselves or treatment thereof. In our study, PE was a 
stronger predictor than DVT for future MI. Thus, it can be hypothesized that local 
disturbances in the cardiopulmonary circulation caused by PE may predispose for clotting in 
the coronary arteries. In addition, a paradoxical embolism from a venous source through a 
patent foramen ovale may lead to ischemic stroke and MI.36, 37 Vascular calcification is 
associated with increased cardiovascular risk. In animal models, treatment with vitamin K 
antagonists led to arterial calcification,38 and long-term use of vitamin K antagonists was 
associated with extracoronary vascular calcification in humans, even after adjustments for 
other risk factors.39 Thus, hypothetically, long-term treatment of VTE with vitamin K 
antagonists could lead to arterial thrombotic disease through arterial calcification.  
VTE was not associated with higher risk of arterial events in elderly men. Although 
these findings should be interpreted with caution due to limited statistical power in subgroup 
analyses, it may shed light over differential pathogenesis of arterial thrombotic disease in men 
and women. In general, women have lower risk of arterial events and are older at time of 
diagnosis than men with similar risk profiles.40 The risk factors associated with arterial events 
in females are found to cluster after menopause.41 Furthermore, women are likely to be 
exposed to risk factors for VTE earlier in life because of oral contraceptive use or pregnancy. 




A hypercoagulable state is found to play an important part in development of arterial events in 
younger subjects.42 Thus, if arterial and venous thrombosis are caused by common risk factors 
other than atherosclerosis, a VTE may be more likely to occur before an arterial event in 
women and young men, whereas elderly men may be more prone to develop arterial events, 
irrespective of other risk factors, due to their high atherosclerotic burden.40  
The highest incidence rate of arterial thrombotic disease, MI and ischemic stroke was 
found the first year after a PE event. As the median duration of anticoagulant therapy after a 
PE was 12 months, many of the arterial thrombotic events occurred during anticoagulant 
treatment. Oral anticoagulant treatment efficiently reduces the risk of MI and cerebrovascular 
events.43, 44 Thus, it is likely to assume that the observed risk estimates are underestimations 
of the true risk of arterial events after a VTE in our study. This may also explain why our 
crude incidence rates of arterial thrombotic diseases after a VTE event were lower than those 
reported in previous cohort studies4-7 in which only VTE subjects who had completed oral 
anticoagulant treatment,4 survived the first month after the VTE event,7 or had no indication 
for long-term anticoagulant therapy5, 7 were included. Moreover, the fact that we followed all 
VTE patients from the initial stage of the disease (including the 207 (17.1%) subjects who 
died within a year after the VTE episode and no longer were at risk of developing arterial 
thrombotic disease), and that all subjects with a history of cancer before enrolment (who are 
also at increased risk of arterial thrombotic events45), were excluded from the DCH Study 
may additionally explain the lower incidence rate.  
Our findings may have some clinical implications. Even though only 1% of the arterial 
thrombotic events in the total population could be attributed to incident venous 
thromboembolism, 64% of the arterial thrombotic events among the VTE patients were due to 
the incident VTE. Recent randomized controlled trials reported that acetylsalicylic acid 
(ASA) reduced the risk of recurrent VTE and major vascular events in patients with 




unprovoked VTE without increasing the risk of bleeding.46, 47 ASA reduced the risk of major 
vascular events by 34% and recurrent VTE by 28%.47 Extrapolated to our population, this 
may suggest prevention of 3 out of the 9 per 1000 major arterial events attributable to VTE in 
our population, and 50 out of the 180 per 1000 recurrent VTE events found in the randomized 
controlled trial. 
The main strengths of our study include the prospective design, large number of 
participants recruited from a general population, wide age distribution, long-term follow-up, 
and validated events of VTE and arterial thrombotic disease. However, the study has some 
limitations. Non-response bias is a possible limitation of cohort studies as those who 
participate in cohort studies tend to be healthier than the general population. The risk 
estimates may therefore be lower than expected. Furthermore, due to a low number of both 
exposure and outcome events in our cohort, we may have lacked the statistical power to 
assess the potential impact of VTE on risk of arterial thrombotic disease in some subgroup-
analyses. 
In conclusion, our cohort study implies that all women and men below 65 years of age 
with incident VTE have increased risk of future arterial thrombotic disease, including 
myocardial infarction and ischemic stroke. However, only 1% of the arterial thrombotic 
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Figure legend:  
 
Figure 1.  
Changes in crude incidence rate per 1000 person-years of arterial thrombotic disease (a), 
myocardial infarction (b) and ischemic stroke (c) with time after an episode of venous 

























Table 1. Baseline characteristics of participants without venous thromboembolism (VTE) or 
arterial thrombotic disease (ATD), with VTE only, ATD only, and ATD after VTE during 
follow-up (n= 81 687). P values denote statistical differences between the four groups. 
 No event 
(n = 74 225) 
VTE only 
(n = 1 118) 
ATD only 
(n= 6 254) 
VTE & 
ATD 
(n = 90) 
P 
% (n)/ mean ± SD      
Age (years) 53 ± 10 57 ± 10 60 ± 9 62 ± 10 < 0.001 
Sex (male) 45.5 (33 764) 50.9 (569) 63.1 (3 949) 51.1 (46) < 0.001 
BMI (kg/ m²) 25.6 ± 4.0 26.8 ± 4.4 26.8 ± 4.2 28.5 ± 4.6 < 0.001 
Self-reported diabetes 1.6 (1 187) 2.4 (27) 5.1 (318) 5.6 (5) < 0.001 
Hypertension* 19.8 (14 708) 29.3 (328) 44.6 (2 792) 55.6 (50) < 0.001 
Hypercholesterolemia† 14.0 (10 378) 24.1 (269) 31.1 (1 942) 33.3 (30) < 0.001 
Smoking‡ 35.3 (26 174) 37.1 (414) 46.6 (2 912) 41.1 (37) < 0.001 
Physical activity§ 58.8 (43 420) 51.2 (572) 46.0 (2 877) 37.8 (34) < 0.001 
Educationǁ 24.7 (18 344) 19.1 (213) 15.7 (980) 11.1 (10) < 0.001 
* Mean systolic/diastolic blood pressure ≥ 140/≥ 90 mmHg, use of blood pressure lowering 
drugs or self-reported hypertension. 
† Total cholesterol ≥ 6.5 mmol/L, use of lipid lowering drugs or self-reported 
hypercholesterolemia. 
‡ Self-reported daily smoking, yes/no. 
§ ≥1 hour of moderate or high physical activity per week, yes/no. 
ǁ >10 years of education. 
 
 






Table 2. Characteristics of venous thromboembolism (VTE) events (n=1 208). 
 % (n) 
Clinical characteristics*  
Deep vein thrombosis 53.6 (648) 
Pulmonary embolism 35.1 (424) 
Unprovoked VTE 42.5 (513) 
Provoked VTE 45.4 (548) 
Clinical risk factors  
Estrogen use† 17.2 (208) 
Other medical conditions‡ 12.1 (146) 
* Information on localization (deep vein thrombosis or pulmonary embolism) available in n= 
1 072. Information on classification (unprovoked or provoked) available in n= 1 061. 
† Current or previous use of hormone replacement therapy or oral contraceptives. 
‡ Myocardial infarction, congestive heart failure, cerebrovascular disease, chronic pulmonary 











Table 3. Incidence rates (IR) and hazard ratios (HR) with 95% confidence interval (CI) for 
arterial thrombotic disease (ATD), myocardial infarction (MI) and ischemic stroke after 
venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism 
(PE). 
  




IR(95% CI) * HR (95% CI) † HR (95% CI) †‡ 
Total ATD      
No VTE  967 604 6 254 6.5 (6.3-6.6) Ref. Ref. 
VTE 5 039 90 17.9 (14.5-22.0) 1.42 (1.15-1.75) 1.35 (1.09-1.66) 
DVT 3 277 49 14.9 (11.3-19.8) 1.13 (0.85-1.50) 1.07 (0.81-1.42) 
PE 1 870 42 22.5 (16.6-30.4) 1.89 (1.40-2.57) 1.82 (1.35-2.47) 
MI      
No VTE 948 179 3 613 3.8 (3.7-3.9) Ref. Ref. 
VTE 4 887 53 10.8 (8.3-14.2) 1.40 (1.07-1.84) 1.31 (1.00-1.72) 
DVT 3 182 26 8.2 (5.6-12.0) 0.98 (0.66-1.44) 0.92 (0.63-1.36) 
PE 1 813 27 14.9 (10.2-21.7) 2.16 (1.48-3.16) 2.02 (1.38-2.95) 
Ischemic stroke      
No VTE 941 549 2 641 2.8 (2.7-2.9) Ref. Ref. 
VTE 4 874 37 7.6 (5.5-10.5) 1.37 (0.99-1.90) 1.33 (0.96-1.84) 
DVT 3 189 23 7.2 (4.8-10.8) 1.26 (0.83-1.90) 1.21 (0.80-1.83) 
PE 1 793 15 8.4 (5.0-13.9) 1.55 (0.93-2.57) 1.53 (0.92-2.55) 
* Per 1000 person-years. 
† Age (as time scale) and sex-adjusted HR  
‡ Adjusted for age, sex, BMI, diabetes, hypertension, hypercholesterolemia, smoking, 
physical activity, education level. 
  




Table 4. Age and sex-stratified incidence rates (IR) and hazard ratios (HR) with 95% 
confidence interval (CI) for arterial thrombotic disease (ATD), myocardial infarction (MI) 
and ischemic stroke after venous thromboembolism (VTE), deep vein thrombosis (DVT) and 
pulmonary embolism (PE). 
 Person-years 
ATD-
events IR(95% CI) * HR (95% CI) † 
Multivariable 
HR(95% CI) †‡ 
Total ATD      
Women < 65      
No VTE 359 227 744 2.1 (1.9-2.2) Ref. Ref. 
VTE 892 9 10.1 (5.2-19.4) 4.08 (2.11-7.88) 3.28 (1.69-6.35) 
DVT 546 6 11.0 (4.9-24.5) 4.45 (1.99-9.94) 3.32 (1.48-7.44) 
PE 350 3 8.57 (2.8-26.6) 3.42 (1.10-10.62) 3.10 (0.99-9.66) 
Women ≥ 65      
No VTE 165 106 1 561 9.5 (9.0-9.9) Ref. Ref. 
VTE 1 450 35 24.1 (17.3-33.6) 1.63 (1.16-2.28) 1.55 (1.11-2.18) 
DVT 843 19 22.5 (14.4-35.3) 1.44 (0.92-2.27) 1.40 (0.89-2.21) 
PE 655 16 24.4 (15.0-39.9) 1.76 (1.07-2.88) 1.64 (1.00-2.69) 
Men < 65      
No VTE 319 284 1 835 5.7 (5.5-6.0) Ref. Ref. 
VTE 1 255 20 15.9 (10.3-24.7) 2.24 (1.44-3.48) 2.06 (1.32-3.20) 
DVT 908 10 11.0 (5.9-20.5) 1.55 (0.83-2.89) 1.40 (0.75-2.61) 
PE 354 10 28.2 (15.2-52.5) 3.87 (2.08-7.20) 3.74 (2.01-6.97) 
Men ≥ 65      
No VTE 123 986 2 114 17.0 (16.3-17.8) Ref. Ref. 
VTE 1 442 26 18.0 (12.3-26.5) 0.85 (0.57-1.25) 0.83 (0.56-1.22) 
DVT 979 14 14.3 (8.5-24.1) 0.64  (0.38-1.08) 0.61 (0.32-1.04) 
PE 511 13 25.5 (14.8-43.8) 1.31 (0.76-2.26) 1.36 (0.79-2.34) 
MI      
Women < 65      
No VTE 355 271 337 0.9 (0.8-1.1) Ref. Ref. 
VTE 864 5 5.8 (2.4-13.9) 5.21 (2.15-12.62) 3.62 (1.49-8.80) 
DVT 524 3 5.7 (1.8-17.8) 5.16 (1.66-16.10) 3.35 (1.07-10.46) 
PE 345 2 5.8 (1.4-23.2) 5.16 (1.28-20.74) 4.06 (1.00-16.40) 
Women ≥ 65      
No VTE 160 591 828 5.2 (4.8-5.5) Ref. Ref. 
VTE 1 401 19 13.6 (8.6-21.3) 1.54 (0.98-2.44) 1.41 (0.89-2.24) 




DVT 814 11 13.5 (7.5-24.4) 1.46 (0.80-2.66) 1.37 (0.76-2.51) 
PE 636 8 12.6 (6.3-25.2) 1.54 (0.77-3.10) 1.36 (0.68-2.74) 
Men < 65      
No VTE 312 631 1 187 3.8 (3.6-4.2) Ref. Ref. 
VTE 2 147 13 10.6 (6.2-18.3) 2.32 (1.34-4.01) 2.11 (1.22-3.65) 
DVT 879 5 5.7 (2.4-13.7) 1.24 (0.51-2.98) 1.10 (0.46-2.65) 
PE 349 8 22.9 (11.5-45.8) 4.89 (2.44-9.81) 4.80 (2.39-9.62) 
Men ≥ 65      
No VTE 1 221 1 261 10.5 (10.0-11.1) Ref. Ref. 
VTE 1 401 16 11.4 (7.0-18.6) 0.84 (0.51-1.38) 0.81 (0.50-1.34) 
DVT 965 7 7.2 (3.5-15.2) 0.50 (0.24-1.04) 0.47 (0.22-1.00) 
PE 484 9 18.6 (9.7-35.8) 1.59 (0.82-3.06) 1.65 (0.85-3.18) 
Ischemic 
stroke      
Women < 65      
No VTE 355 440 407 1.1 (1.0-1.3) Ref. Ref. 
VTE 864 4 4.6 (1.7-12.3) 3.34 (1.25-8.95)  3.16 (1.18-8.47) 
DVT 529 3 5.7 (1.8-17.6) 4.12 (1.32-12.83) 3.66 (1.17-11.42) 
PE 338 1 2.9 (0.4-22.0) 2.08 (0.29-14.79) 2.14 (0.30-15.30) 
Women ≥ 65      
No VTE 159 963 733 4.6 (4.3-4.9) Ref. Ref. 
VTE 1 404 16 11.4 (7.0-18.6) 1.67 (1.02-2.75) 1.66 (1.01-2.74) 
DVT 812 8 9.9 (4.9-19.7) 1.40 (0.70-2.81) 1.42 (0.70-2.86) 
PE 641 8 12.5 (6.2-25.0) 1.89 (0.94-3.80) 1.81 (0.90-3.65) 
Men < 65      
No VTE 308 473 648 2.1 (1.9-2.3) Ref. Ref. 
VTE 1 199 7 5.8 (2.8-12.2) 2.13 (1.01-4.50) 1.95 (0.93-4.12) 
DVT 883 5 5.7 (2.4-13.6) 2.09 (0.87-5.03) 1.88 (0.80-4.54) 
PE 324 2 6.2 (1.5-24.6) 2.16 (0.54-8.65) 2.08 (0.52-8.34) 
Men ≥ 65      
No VTE 117 674 853 7.2 (6.8-7.7) Ref. Ref. 
VTE 1 407 10 7.1 (3.8-13.2) 0.79 (0.42-1.47) 0.77 (0.41-1.44) 
DVT 965 7 7.2 (3.5-15.2) 0.77 (0.37-1.62) 0.74 (0.35-1.56) 
PE 490 4 8.2 (3.1-21.8) 0.98 (0.37-2.63) 1.02 (0.38-2.72) 
* Per 1000 person-years. 
† Age (as time scale).  
‡ Adjusted for age, BMI, diabetes, hypertension, hypercholesterolemia, smoking, physical 
activity, education level.  
 
